Healthcare
Shanghai Pharmaceuticals Holding Co., Ltd(SHPMY)
Live Price
Offline$7.60
+0.00% today
Window Change
+11.27%
Window
Jun 23, 2025 โ May 15, 2026
- Market Cap
- $63.38B
- Revenue Growth
- +3.0%
- EPS Growth
- +25.2%
- Dividend Yield
- 2.4%
Coverage: 227 bars ยท Jun 23, 2025 โ May 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Shanghai Pharmaceuticals Holding Co., Ltd (SHPMY) is a Healthcare stock with a market cap of $63.38B and listed on OTC. The stock last traded around $7.60 and up 11.3% across the available one-year price window (Jun 23, 2025 โ May 15, 2026). Baseline metrics include revenue growth of +3.0%, EPS growth of +25.2%, a dividend yield of 2.4%. What stands out right now is revenue +3.0%, EPS +25.2%, free cash flow +11.7% with operating margin 3.5% and ROIC 4.6%. The dividend is present but secondary, with a yield around 2.4%. Valuation is more restrained than many high-expectation growth names at P/E 10.9 and price/sales 0.2. Stock Foundry combines SHPMY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+3.0% vs +7.6% peer median
Operating Margin
Below sector median
+3.5% vs +19.4% peer median
P/E
Below sector median
10.9 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 27, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +3.0% and EPS at +25.2%, with operating margin around 3.5%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 2.4%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 27, 2026 | โ | +0.0% | +0.0% | โ |
2026 Mar 25, 2026 | โ | +0.0% | +0.0% | +0.0% |
2025 Oct 27, 2025 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SHPMY
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SHPMY Max Drawdown
-14.82%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SHPMY and SPY.
Company Overview
Shanghai Pharmaceuticals Holding Co., Ltd
Other OTC
Shanghai Pharmaceuticals Holding Co., Ltd., an investment holding company, researches, develops, manufactures, distributes, and retails pharmaceutical and healthcare products in the People's Republic of China. It operates through four segments: Production, Distribution, Retail, and Others. The company offers chemicals and biochemicals, Chinese medicines, healthcare products, and medical devices in various therapeutic areas, including oncology, cerebrocardiovascular, CNS, general infection, immunology, digestive and metabolism, and respiratory. It provides approximately 700 varieties of drugs. The company also engages in the provision of pharmaceutical distribution, warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it engages in the operation of a network of retail pharmacy stores; online drug business; and provision of consulting services, assets management operations, as well as clinical trials, medical aid, physicians and patients' education, e-prescription management, and remote and cloud hospitals. Further, the company manufactures and trades in medicines. It operates approximately 2,000 retail chain pharmacies in 24 provinces. The company was incorporated in 1994 and is headquartered in Shanghai, the People's Republic of China. Shanghai Pharmaceuticals Holding Co., Ltd. is a subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd.
- Leadership
- Qiuhua Yang
- IPO Date
- Feb 19, 2014
- Employees
- 49.4k
- Street Address
- Shanghai Pharmaceutical Building
- Mailing
- Shanghai, 200020
- Region
- Shanghai, CN
- Reporting Currency
- USD
- Investor Line
- 86 21 6373 0908
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 10.9
- EV/EBITDA
- 9.1
- Price/Sales
- 0.2
- Price/Book
- 0.8
Growth
- Revenue
- +3.0%
- EPS
- +25.2%
- Free Cash Flow
- +11.7%
Profitability
- Gross Margin
- 10.8%
- Operating Margin
- 3.5%
- Net Margin
- 2.0%
- ROE
- 7.6%
- ROIC
- 4.6%
Balance Sheet
- Debt/Equity
- 0.81
- Current Ratio
- 1.34
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.